Business / Finance

RSS

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.

30 Jan 2011

Capital Pro-Égaux shares to continue on NEX

Capital Pro-Égaux Inc. announces that trading in its shares will resume on January 28, 2011 on NEX, a new and separate board of the TSX Venture Exchange.

29 Jan 2011

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

Angiotech Pharmaceuticals, Inc. today announced that, further to its news release issued earlier today, the Company and certain of its subsidiaries have voluntarily commenced proceedings under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction, having obtained an Initial Order from the Supreme Court of British Columbia today.

29 Jan 2011

National Mentor Holdings prices 12.50% senior notes due 2018

National Mentor Holdings, announced today that it has priced an offering of $250 million in aggregate principal amount of 12.50% senior notes due 2018 through a private offering that is exempt from registration under the Securities Act of 1933, as amended.

29 Jan 2011

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.

29 Jan 2011

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.

29 Jan 2011

Viral Genetics enters binding Release and Settlement Agreement with T&T

Viral Genetics, and its President, Haig Keledjian, have entered into a binding Release and Settlement Agreement with Timothy and Thomas LLC and its principals that was approved by the court.

29 Jan 2011

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.

29 Jan 2011

PHM announces financial results for quarter and year ended September 30, 2010

Patient Home Monitoring, a company focused on in-home cardiology healthcare services, today announced financial results for the quarter and year ended September 30, 2010.

29 Jan 2011

Bionovo prices public offering of common stock at $1.30 per share

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the pricing of its previously announced underwritten public offering, to sell up to 30,031,200 units at a price per unit of $1.00 for aggregate gross proceeds of approximately $30 million.

29 Jan 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

Covalon Technologies' annual revenue up 54%

Covalon Technologies Ltd., an advanced medical technologies company, today announced the following financial results for its year ended September 30, 2010

29 Jan 2011

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

Awarepoint ends 2010 with 91 hospital sites contract containing RTLS network coverage

Awarepoint Corporation, a privately held San Diego-based corporation, today announced it ended 2010 with 91 hospital sites contracted consisting of 45,062,013 million square feet of real-time location system network coverage in U.S. hospitals and 135,265 healthcare assets under management.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011

Synutra International renews manufacturing license for its primary production facility

Synutra International, Inc., a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today announced that it has renewed its manufacturing license for its primary production facility with the Shandong Bureau of Quality and Technical Supervision.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2010 increased 5% to $283.8 million, from $270.3 million for the fourth quarter of 2009. Organic revenue growth, as defined below, was 6%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2010 increased 22% to $0.62, compared to $0.51 for the same period in the prior year.

28 Jan 2011

H.I.G. urges Matrixx shareholders to evaluate BML Letter regarding pending tender offer

H.I.G. Capital, LLC, a leading global private investment firm, today announced that it has reviewed the letter addressed to the Board of Directors of Matrixx Initiatives, Inc. from BML Capital Management, LLC, dated January 25, 2011, regarding the pending tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx.

28 Jan 2011

Business / Finance

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Capital Pro-Égaux shares to continue on NEX

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

National Mentor Holdings prices 12.50% senior notes due 2018

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Viral Genetics enters binding Release and Settlement Agreement with T&T

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

PHM announces financial results for quarter and year ended September 30, 2010

Bionovo prices public offering of common stock at $1.30 per share

Adeona to sell 2.85 million common stock at $1.40 per share

Covalon Technologies' annual revenue up 54%

Athersys enters definitive agreements to sell common stock, warrants

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Awarepoint ends 2010 with 91 hospital sites contract containing RTLS network coverage

BioTime announces acquisition of CTI assets

Synutra International renews manufacturing license for its primary production facility

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

H.I.G. urges Matrixx shareholders to evaluate BML Letter regarding pending tender offer

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News